RAD-x is one of the leading European diagnostic imaging practice operators focusing on Germany and Switzerland. RAD-x grows by acquiring successful diagnostic imaging centers whose radiologists are looking for a solution for their succession and who will continue operating their practice in the collective RAD-x network.

We invested in and, together with the founders, set-up RAD-x in 2016. Since the partnership with the first diagnostic imaging center, RAD-x has successfully grown into a leading Pan-European operator of diagnostic imaging centers with 23 sites, more than 130 doctors and 750 staff across Germany and Switzerland, now performing more than 400,000 examinations annually.

As part of its buy-and-build strategy, the group acquired and successfully integrated 12 DICs, a rheumatology clinic in Germany (regulatory vehicle) as well as a teleradiology provider growing the combined revenues to over €90M at exit.

Throughout the holding period, RAD-x has invested strongly in the acquired practices: in Geneva for example, RAD-x supported and executed the move of one its sites to a brand-new location with the latest MRI and CT equipment. In Bonn, RAD-x enabled the installation of the latest model PET/ CT, making the site one of the first in Germany to offer these high-quality nuclear medicine services. Furthermore, RAD-x supports best practices sharing across its centers and assists the practices with general management services including digitalization, procurement, finance, recruitment, hospital partnerships and site development. Finally, RAD-x offers teleradiology services to support hospitals and diagnostic imaging groups with overload and emergency diagnostic services.

We strongly adhered to RAD-x’ vision of providing high quality and efficient patient-care by combining the forces of strong diagnostic imaging practices, exchanging best practices across centers, investments in people and equipment and centralizing non-core processes.

Martin Hardens (RAD-x CEO): “Gilde Healthcare have been very good partners for us since our inception in 2016: their rigorous approach combined with a deep understanding of European healthcare markets has been invaluable in our development.”

Gilde Healthcare exited RAD-x in 2024 to a consortium of financial investors Swiss Life Asset Managers and Vesper Infrastructure who will further drive growth of the RAD-x platform.